Recently, anifrolumab, the anti‐IFNAR1 mAb, has shown efficacy in moderate‐to‐severe SLE in a Phase III clinical trial,11 in which a BILAG‐based composite lupus assessment (BICLA) response occurred in 86 of 180 (47.8%) patients who received anifrolumab at week 52, compared with 57 of 182 (31.5%) of those who received placebo. Here, IFNAR1 is linked to systemic lupus erythematosus.